

QoN 003-01 In your submission you state that *“the restriction of nicotine vaping products to sale by chemists after a GP visit is problematic”* because *“it will require a significant number of Medicare funded GP appointments that could be better utilised by our health system.*

How many additional GP appointments does Ampol believe will happen as a result of *“the restriction of nicotine vaping products to sale by chemists after a GP visit”*?

It is self-evident that at least one GP appointment would be required for each smoker who wishes to switch. There may also be multiple appointments sought by a smoker who wished to switch to vaping whose GP pushes other quit products which would illuminate nicotine addition all together.

Ampol has submitted that if a person is motivated to switch to vaping and wants to make that choice, they could make that choice at a retail setting where they would normally purchase cigarettes.

If a smoker or nicotine-vaper is interested in quitting nicotine addiction, a GP visit would be appropriate.

b. What modelling has Ampol done to back up this claim?

We have not conducted modelling on this claim but note from media reports that other individuals and organisations may be better placed to provide further information.

Does Ampol have any modelling it can point to back up this claim?

No, Ampol has not invested in this type of modelling and it is unlikely that we would do so.

If so, please provide the modelling to the committee.

NA

QoN 003-02 What does Ampol/Caltex anticipate being the market value of allowing nicotine e-cigarettes to be available for sale as a consumer product?

Using New Zealand as the most comparable market, we estimate the Australian market could be worth approximately \$1.66 billion.

QoN 003-03 Has Ampol/Caltex done any modelling of what the value of being able to sell nicotine e-cigarette products at their stores would be worth to them?

No, we are relying on external sources for the above estimate.

QoN 003-04 If Ampol/Caltex was able to legally sell e-cigarettes as a reduced harm product, would it discontinue the sale of traditional combustible cigarettes?

Ampol would continue to offer customers a choice of products while ever the sale of those products is legal and it remains economic to do so.

QoN 003-05 Does Ampol/Caltex have any plans to phase or stop the sale of traditional combustible cigarettes?

No

QoN 003-06 Do any Ampol/Caltex sell e-cigarettes currently?

We have trialled the sale of non-nicotine e-cigarettes.

QoN 003-09 Has Ampol made submissions to the Department of Health regarding the regulation of e-cigarettes in the past five years?

No

QoN 003-10 Has Ampol made submissions to the Therapeutic Goods Administration regarding the regulation of e-cigarettes in the past five years?

No

QoN 003-11 Please indicate if Ampol consulted any of the below groups about your submission to this inquiry, or regarding your policy on vaping, tobacco, nicotine or any related products:

- a. The Institute for Public Affairs;
- b. Centre for Independent Studies;
- c. The Sydney Institute;
- d. Australian Taxpayers Alliance;
- e. Australian Institute For Progress;
- f. Mannkal Economic Education Foundation; and
- g. any ATLAS network member organization

No